CL2014002919A1 - Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo. - Google Patents

Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo.

Info

Publication number: CL2014002919A1
Authority: CL; Chile
Prior art keywords: indole; methyl; treatment; combination; pharmaceutical composition
Prior art date: 2012-05-04

Application number

CL2014002919A

Other languages

English (en)

Inventor

Christopher Michael Adams

Charles Babu

Michael Paul Capparelli

Jian Ding

Takeru Ehara

Keith Jendza

Rajeshri Ganesh Karki

Toshio Kawanami

Liang Xue

Nello Mainolfi

James J Powers

Michael H Serrano-Wu

Nan Ji

Chun Zhang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-04

Filing date

2014-10-28

Publication date

2015-07-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48626502&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002919(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-10-28 Application filed by Novartis Ag filed Critical Novartis Ag

2015-07-03 Publication of CL2014002919A1 publication Critical patent/CL2014002919A1/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

CL2014002919A 2012-05-04 2014-10-28 Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo. CL2014002919A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261642798P	2012-05-04	2012-05-04
US201361782820P	2013-03-14	2013-03-14

Publications (1)

Publication Number	Publication Date
CL2014002919A1 true CL2014002919A1 (es)	2015-07-03

Family

ID=48626502

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002919A CL2014002919A1 (es)	2012-05-04	2014-10-28	Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo.

Country Status (25)

Country	Link
EP (1)	EP2855456B1 (es)
JP (1)	JP6180514B2 (es)
KR (1)	KR20150003903A (es)
CN (1)	CN104603127B (es)
AP (1)	AP2014008040A0 (es)
AR (1)	AR090945A1 (es)
AU (1)	AU2013255470B2 (es)
BR (1)	BR112014027359A2 (es)
CA (1)	CA2872000A1 (es)
CL (1)	CL2014002919A1 (es)
CR (1)	CR20140508A (es)
EA (1)	EA027113B1 (es)
ES (1)	ES2630079T3 (es)
HK (1)	HK1206017A1 (es)
IL (1)	IL235362A0 (es)
MX (1)	MX2014013428A (es)
PE (1)	PE20150623A1 (es)
PH (1)	PH12014502462A1 (es)
PL (1)	PL2855456T3 (es)
PT (1)	PT2855456T (es)
SG (1)	SG11201406973PA (es)
TN (1)	TN2014000449A1 (es)
TW (1)	TW201348199A (es)
UY (1)	UY34781A (es)
WO (1)	WO2013164802A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2970269B1 (en)	2013-03-14	2017-04-19	Novartis AG	2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
JO3425B1 (ar) *	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9676728B2 (en)	2013-10-30	2017-06-13	Novartis Ag	2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
CN103755622A (zh) *	2013-12-25	2014-04-30	华东理工大学	合成4,5,6,7-四氘代吲哚-3-乙酸的方法
ES2908479T3 (es)	2015-08-26	2022-04-29	Achillion Pharmaceuticals Inc	Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
TW202222786A (zh)	2016-02-01	2022-06-16	美商百歐克斯製藥公司	苯并吡唑化合物及其類似物
ES2902006T3 (es) *	2016-06-27	2022-03-24	Achillion Pharmaceuticals Inc	Quinazolina y compuestos indol para tratar trastornos médicos
KR102632860B1 (ko)	2017-03-01	2024-02-02	아칠리온 파르마세우티칼스 인코포레이티드	의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
TW202010742A (zh) *	2018-04-06	2020-03-16	美商百歐克斯製藥公司	取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
US20230022157A1 (en)	2018-08-20	2023-01-26	Achillion Pharmaceuticals, Inc.	Pharmaceutical compounds for the treatment of complement factor d medical disorders
KR20210093855A (ko)	2018-09-25	2021-07-28	아칠리온 파르마세우티칼스 인코포레이티드	보체 인자 d 억제제의 형태체 형태
CN114057758A (zh)	2020-08-07	2022-02-18	上海美悦生物科技发展有限公司	补体因子b抑制剂及其药物组合物、制备方法和用途
CN114057692B (zh)	2020-08-07	2023-07-21	上海美悦生物科技发展有限公司	一种杂环类化合物、其制备方法及用途
WO2023187715A1 (en) *	2022-04-01	2023-10-05	Novartis Ag	Complement factor b inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT72878B (en)	1980-04-24	1983-03-29	Merck & Co Inc	Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
GB8420919D0 (en) *	1984-08-17	1984-09-19	Beecham Group Plc	Compounds
DE19545464A1 (de) *	1995-12-06	1997-06-12	Bayer Ag	Benzimidazol-isoindoleninfarbstoffe
SI1249450T1 (sl) *	2000-01-17	2008-04-30	Teijin Pharma Ltd	Derivati benzimidola kot inhibitorji humane kimaze
WO2004078163A2 (en)	2003-02-28	2004-09-16	Transform Pharmaceuticals, Inc.	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0400781D0 (en) *	2004-01-14	2004-02-18	Novartis Ag	Organic compounds
CA2582639A1 (en) *	2004-10-08	2006-04-20	Schering Corporation	Thrombin receptor antagonists
WO2007034277A1 (en) *	2005-09-19	2007-03-29	Pfizer Products Inc.	Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists
CA2655694C (en) *	2006-07-03	2014-12-16	Biovitrum Ab (Publ)	1,4-substituted indoles useful for modulation of the 5-ht6 receptor
JO3265B1 (ar) *	2008-12-09	2018-09-16	Novartis Ag	مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
SG172338A1 (en) *	2008-12-22	2011-07-28	Chemocentryx Inc	C5ar antagonists
JP2012518037A (ja) *	2009-02-18	2012-08-09	アムジエン・インコーポレーテツド	ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物
EP2447263A1 (en) *	2010-09-27	2012-05-02	Bioprojet	Benzazole derivatives as histamine H4 receptor ligands
US8846656B2 (en) *	2011-07-22	2014-09-30	Novartis Ag	Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators

2013
- 2013-05-03 BR BR112014027359A patent/BR112014027359A2/pt not_active IP Right Cessation
- 2013-05-03 KR KR1020147033713A patent/KR20150003903A/ko not_active Application Discontinuation
- 2013-05-03 MX MX2014013428A patent/MX2014013428A/es unknown
- 2013-05-03 PE PE2014001943A patent/PE20150623A1/es not_active Application Discontinuation
- 2013-05-03 JP JP2015509561A patent/JP6180514B2/ja not_active Expired - Fee Related
- 2013-05-03 CA CA2872000A patent/CA2872000A1/en not_active Abandoned
- 2013-05-03 SG SG11201406973PA patent/SG11201406973PA/en unknown
- 2013-05-03 AU AU2013255470A patent/AU2013255470B2/en not_active Ceased
- 2013-05-03 AP AP2014008040A patent/AP2014008040A0/xx unknown
- 2013-05-03 PT PT137290961T patent/PT2855456T/pt unknown
- 2013-05-03 TW TW102115970A patent/TW201348199A/zh unknown
- 2013-05-03 EP EP13729096.1A patent/EP2855456B1/en active Active
- 2013-05-03 PL PL13729096T patent/PL2855456T3/pl unknown
- 2013-05-03 UY UY0001034781A patent/UY34781A/es not_active Application Discontinuation
- 2013-05-03 WO PCT/IB2013/053546 patent/WO2013164802A1/en active Application Filing
- 2013-05-03 EA EA201492023A patent/EA027113B1/ru not_active IP Right Cessation
- 2013-05-03 CN CN201380035327.6A patent/CN104603127B/zh active Active
- 2013-05-03 ES ES13729096T patent/ES2630079T3/es active Active
- 2013-05-06 AR ARP130101533A patent/AR090945A1/es unknown
2014
- 2014-10-22 TN TN2014000449A patent/TN2014000449A1/fr unknown
- 2014-10-27 IL IL235362A patent/IL235362A0/en unknown
- 2014-10-28 CL CL2014002919A patent/CL2014002919A1/es unknown
- 2014-11-04 CR CR20140508A patent/CR20140508A/es unknown
- 2014-11-04 PH PH12014502462A patent/PH12014502462A1/en unknown
2015
- 2015-07-09 HK HK15106552.0A patent/HK1206017A1/xx unknown

Also Published As

Publication number	Publication date
AR090945A1 (es)	2014-12-17
JP2015515976A (ja)	2015-06-04
BR112014027359A2 (pt)	2017-07-18
MX2014013428A (es)	2015-02-04
TN2014000449A1 (en)	2016-03-30
CN104603127A (zh)	2015-05-06
PL2855456T3 (pl)	2017-09-29
ES2630079T3 (es)	2017-08-17
PH12014502462A1 (en)	2014-12-22
CR20140508A (es)	2015-03-13
PE20150623A1 (es)	2015-05-17
WO2013164802A1 (en)	2013-11-07
HK1206017A1 (en)	2015-12-31
AU2013255470B2 (en)	2015-09-17
EA201492023A1 (ru)	2015-03-31
TW201348199A (zh)	2013-12-01
KR20150003903A (ko)	2015-01-09
JP6180514B2 (ja)	2017-08-16
AU2013255470A1 (en)	2014-11-13
EP2855456A1 (en)	2015-04-08
EA027113B1 (ru)	2017-06-30
CA2872000A1 (en)	2013-11-07
UY34781A (es)	2013-12-31
SG11201406973PA (en)	2014-12-30
CN104603127B (zh)	2016-10-05
IL235362A0 (en)	2014-12-31
EP2855456B1 (en)	2017-03-29
PT2855456T (pt)	2017-07-10
AP2014008040A0 (en)	2014-10-31

Publication	Publication Date	Title
CL2014002919A1 (es)	2015-07-03	Compuestos derivados de 1h-indol-4-il-metil-(heterociclo benzofusionado); composicion y combinacion farmaceutica; y uso en el tratamiento de un trastorno mediado por la activacion del complemento o la ruta alternativa del mismo.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CO7071129A2 (es)	2014-09-30	Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
CL2015000711A1 (es)	2015-09-04	Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer.
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2014002257A1 (es)	2014-12-05	Compuestos derivados de 6-alquinilo piridinas, como mimeticos smac; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o prevencion del cancer.
CL2013003019A1 (es)	2014-02-14	Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2014000458A1 (es)	2014-09-05	Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades.
CL2015000295A1 (es)	2015-04-24	Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
MA41265A (fr)	2017-10-31	Compositions pour administration de médicaments iléo-jéjunal.
CL2015000873A1 (es)	2015-08-14	Métodos para el tratamiento del síndrome de alport.
CL2013002125A1 (es)	2013-12-20	Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
DK2981274T3 (da)	2020-07-06	Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose
BR112017005255A2 (pt)	2018-07-31	composições não gordurosas de cuidado pessoal.
CL2015001724A1 (es)	2015-10-16	Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros.
CL2015001279A1 (es)	2015-06-26	Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
CL2015001202A1 (es)	2015-07-03	Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
BR112015003259A2 (pt)	2017-08-08	composto, composição farmacêutica, e, composição de vacina.
CL2014003429A1 (es)	2015-03-27	Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CL2015003595A1 (es)	2016-07-08	Inhibidores/antiandrógenos novedosos de cyp17
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2014001861A1 (es)	2014-11-07	Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CL2014002048A1 (es)	2014-11-14	Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras.
CL2014001862A1 (es)	2014-11-14	Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.